Invesco’s Checkpoint Therapeutics CKPT Stock Holding History

Invesco’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,836	Closed	-$89K	–	3974
2021 Q1	$89K	Buy	2,836 +327	+13%	+$11K	﹤0.01%	3772
2020 Q4	$66K	Buy	+2,509	New	+$63.5K	﹤0.01%	3707

Other funds holding CKPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SAG

Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Invesco's CKPT Position: Q2 2021 in Review

Invesco sold out of Checkpoint Therapeutics (CKPT) in Q2 2021, closing a stake of 2,836 shares — an estimated $89K sold.

Invesco first reported a position in CKPT in Q4 2020 and held it in 2 quarters. The position peaked at $89K in Q1 2021. 69 funds tracked by Wall St. Rank hold CKPT as of Q2 2021.

Invesco reported no remaining Checkpoint Therapeutics position as of Q2 2021 after selling out during the quarter.
Invesco sold 2,836 Checkpoint Therapeutics shares in Q2 2021, an estimated $89K.
Invesco first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 2 quarters.
Invesco's Checkpoint Therapeutics position peaked at $89K in Q1 2021.
69 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.